Agios Pharmaceuticals, Inc., a US-based biopharmaceutical company engaged in research of cancer metabolism, has completed its proposed initial public offering (IPO) of 6.772 million shares of common stock, including 0.883 million shares sold pursuant to the underwriters over-allotment option at a price of $18 per share that results in gross proceeds of $121.89 million.
Update on July 23, 2013:
Agios Pharmaceuticals has priced its proposed IPO of 5.888 million shares of common stock at a price of $18 per share to raise gross proceeds of $105.98 million.
In addition, Agios Pharmaceuticals has granted the underwriters a 30-day option to purchase up to 0.883 million additional shares of common stock at the IPO price, less the underwriting discount.
Agios Pharmaceuticals common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol AGIO on July 24, 2013.
Update on July 11, 2013:
Agios Pharmaceuticals has set the price band for its proposed IPO of five million shares of common stock at a price between $14 and $16 per share.
Agios Pharmaceuticals has granted the underwriters a 30-days option to purchase up to an additional 0.75 million shares of common stock, to cover over-allotments.
Announcement (June 10, 2013):
Agios Pharmaceuticals has filed a registration statement with the US Securities and Exchange Commission (SEC) for a proposed IPO of common stock to raise maximum aggregate proceeds of $86 million.
Agios Pharmaceuticals intends to list common stock on The NASDAQ Global Market under the symbol AGIO.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers, while Cowen and Company, LLC and Leerink Swann LLC are acting as underwriters to the offering. Wilmer Cutler Pickering Hale and Dorr LLP is acting as advisor to Agios Pharmaceuticals on certain legal matters.